Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | DGKA | P23743 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614868 | 0.81 | TSHR (0.50) | ALDH1A1LMNAPTGS1TSHRTDP1 | |
| SCHEMBL3048368 | 0.80 | TSHR (0.56) | ALDH1A1MEN1LMNABLMHBB | |
| SCHEMBL1539244 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNAPTGS1TSHRTDP1 | |
| SCHEMBL7845680 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNAPTGS1TSHRTDP1 | |
| SCHEMBL338444 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNAPTGS1TSHRTDP1 | |
| SCHEMBL28687285 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNAPTGS1TSHRTDP1 | |
| SCHEMBL11514647 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNAPTGS1TSHRTDP1 | |
| SCHEMBL1539265 | 0.79 | ALDH1A1 (0.47) | ALDH1A1LMNAPTGS1TSHRTDP1 | |
| SCHEMBL11830731 | 0.78 | TSHR (0.54) | ALDH1A1MEN1LMNABLMHBB | |
| SCHEMBL11830603 | 0.78 | TSHR (0.54) | ALDH1A1MEN1LMNABLMHBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114957-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA Laboratories Limited (IN) | 2009-11-11 | — | — | EP | claimed |
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | US | claimed |
| WO-2008093357-A2 | PROCESS FOR PREPARATION OF CRYSTALLINE CLOPIDOGREL HYDROGEN SULPHATE FORM I | IPCA LABORATORIES LIMITED (IN) | 2008-08-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188663-A1 | Process for the preparation of crystalline clopidogrel hydrogen sulphate Form I | CYP2S1, CYP2F1, VKORC1L1 | ALDH1A1 1578/4885MEN1 4084/4885LMNA 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.